Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading 7.7% Higher – What’s Next?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was up 7.7% during trading on Thursday . The stock traded as high as $29.65 and last traded at $29.65. Approximately 172,714 shares changed hands during trading, a decline of 54% from the average daily volume of 377,342 shares. The stock had previously closed at $27.53.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. HC Wainwright initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, June 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Down 7.3%

The stock has a market capitalization of $1.76 billion, a PE ratio of -5.11 and a beta of 1.46. The stock has a fifty day moving average of $24.33 and a 200-day moving average of $25.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Large investors have recently bought and sold shares of the business. Two Sigma Investments LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth about $76,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Connective Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $100,000. Sigma Planning Corp purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $334,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.